VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
IH
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
IHiHuman Inc.
$1.00$10M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. IH
  4. Financial Ratios

iHuman Inc. (IH) Financial Ratios

Latest Ratios: P/E Ratio 2.8x · EV/EBITDA -119.5x · ROE 9.8%. (2018–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

IH Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Market Cap$10M$22M$18M$34M$28M$30M$164M——
Enterprise Value$-160716500$-1117992126$-1090045880$-1176288658$-1012880680$-791253440$-691016768——
P/E Ratio →2.850.240.190.190.26————
P/S Ratio0.090.030.020.030.030.030.31——
P/B Ratio0.070.020.020.040.040.050.26——
P/FCF—0.500.360.200.025.030.79——
P/OCF1.370.450.310.200.020.780.74——

P/E links to full P/E history page with 30-year chart

IH EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
EV / Revenue—-1.39-1.18-1.16-1.03-0.84-1.30——
EV / EBITDA-119.51-15.01-12.74-6.86-8.27————
EV / EBIT-16.06-10.98-9.86-5.81-7.63————
EV / FCF—-24.76-21.33-7.10-0.81-133.41-3.34——

IH Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Gross Margin67.9%67.9%69.4%70.8%70.1%69.9%68.7%61.5%50.1%
Operating Margin8.3%8.3%7.8%15.7%11.3%-5.7%-8.4%-127.5%-16.7%
Net Profit Margin11.8%11.8%10.7%17.8%11.1%-3.9%-7.0%-126.0%-13.3%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
ROE9.8%9.8%10.3%20.9%15.9%-5.9%-11.9%——
ROA6.8%6.8%6.9%13.0%9.0%-3.5%-6.2%-242.9%-30.0%
ROIC—————————
ROCE6.8%6.8%7.4%18.5%16.1%-8.6%-14.0%——

IH Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Debt / Equity0.010.010.020.000.010.060.01——
Debt / EBITDA0.150.150.170.020.07————
Net Debt / Equity—-1.15-1.15-1.26-1.35-1.35-1.33——
Net Debt / EBITDA-15.31-15.31-12.95-7.05-8.50————
Debt / FCF—-25.26-21.69-7.31-0.84-138.44-4.13-2.61—
Interest Coverage—————————

Net cash position: cash ($1.2B) exceeds total debt ($11M)

IH Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Current Ratio3.573.572.982.822.232.102.560.890.47
Quick Ratio3.513.512.932.782.202.042.520.780.23
Cash Ratio3.163.162.612.471.871.772.160.570.05
Asset Turnover—0.590.650.700.740.860.511.302.25
Inventory Turnover12.1212.1212.0117.9715.3910.139.874.072.22
Days Sales Outstanding—23.2521.4022.4630.3322.7953.7235.0337.71

IH Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Dividend Yield53.2%100.0%100.0%———40.2%——
Payout Ratio39.9%39.9%35.8%——————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Earnings Yield35.1%416.7%532.5%537.5%390.4%————
FCF Yield—200.8%278.7%492.6%4434.8%19.9%126.2%——
Buyback Yield24.5%74.4%52.5%28.4%24.8%0.5%0.0%——
Total Shareholder Yield77.7%100.0%100.0%28.4%24.8%0.5%40.2%——
Shares Outstanding—$11M$11M$11M$11M$11M$9M$11M$11M

Key Metrics

Growth RegimeContracting
ProfitabilityModerate
Balance SheetFortress
Cash FlowMixed
Top Statement Risk

Capital deployment and demographic headwinds

Market Pricing Reflects Terminal Skepticism

Based on reported figures, iHuman trades at a P/S ratio of 0.12 and a P/E of 1.09, suggesting that the market is heavily discounting the company's future growth potential and effectively valuing the firm as a liquidating entity rather than a going concern.

The extreme compression in valuation multiples relative to historical norms indicates that investors are placing little to no value on the company's core educational services. This pricing disconnect warrants further investigation into whether the market is overestimating the regulatory risk or if the current cash-heavy balance sheet is being viewed as trapped capital.

Margin Compression Amid Operational Stagnation

As reported in recent financial statements, iHuman's operating margin has contracted to 9.7% in 2025Q2 from 21.4% in 2023Q1, highlighting a failure to maintain operating leverage as the company struggles to offset declining revenue with cost-cutting measures.

While the gross margin remains robust at 67.8%, the significant drop in operating profitability suggests that fixed costs, particularly in content development and marketing, are becoming increasingly burdensome. Investors should monitor whether management can stabilize these margins or if the current cost structure is fundamentally misaligned with the shrinking addressable market.

Capital Efficiency Decaying Under Pressure

According to recent financial data, iHuman's ROE has fluctuated significantly, dropping from 6.8% in 2023Q1 to 3.3% in 2025Q2, which indicates a diminishing ability to generate meaningful returns on equity as the company's core business model faces persistent top-line headwinds.

The decline in return metrics appears to be driven by the combination of revenue contraction and the accumulation of idle cash on the balance sheet, which dilutes overall capital efficiency. This trend suggests that the company is currently failing to compound shareholder value effectively, necessitating a strategic pivot or more aggressive capital allocation.

Working Capital Efficiency Remains Stable

Based on the latest quarterly filings, iHuman's cash conversion cycle remains relatively stable at 23 days, suggesting that the company maintains efficient control over its inventory and receivables despite the broader challenges facing its educational product segment.

The consistency in DSO and DIO metrics indicates that the company's operational processes are not currently suffering from the same deterioration as its top-line growth. However, this efficiency may be masking underlying demand issues, as the company may be clearing inventory at the expense of future growth potential.

Misapplication of P/E Ratio Metrics

The P/E ratio is frequently misapplied to iHuman's business model, as it fails to account for the massive cash-to-market-cap disparity that distorts earnings-based valuation multiples and obscures the company's true operational health.

Because iHuman holds a significant cash position relative to its market capitalization, the P/E ratio provides a misleading picture of the company's profitability. Analysts should instead utilize an EV/EBITDA metric or a cash-adjusted P/E to better understand the underlying earning power of the core business, excluding the impact of interest income.

Download Financial Ratios Data

Includes 30+ ratios · 8 years · Updated daily

Consensus & Technical Research Suite
Open IH Terminal

IH Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

IH — Frequently Asked Questions

Quick answers to the most common questions about buying IH stock.

What is iHuman Inc.'s P/E ratio?

iHuman Inc.'s current P/E ratio is 2.8x. The historical average is 0.2x. This places it at the 100th percentile of its historical range.

What is iHuman Inc.'s EV/EBITDA?

iHuman Inc.'s current EV/EBITDA is -119.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.

What is iHuman Inc.'s ROE?

iHuman Inc.'s return on equity (ROE) is 9.8%. The historical average is 6.5%.

Is IH stock overvalued?

Based on historical data, iHuman Inc. is trading at a P/E of 2.8x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What is iHuman Inc.'s dividend yield?

iHuman Inc.'s current dividend yield is 53.24% with a payout ratio of 39.9%.

What are iHuman Inc.'s profit margins?

iHuman Inc. has 67.9% gross margin and 8.3% operating margin.

How much debt does iHuman Inc. have?

iHuman Inc.'s Debt/EBITDA ratio is 0.2x, indicating low leverage. A ratio below 2x is generally considered financially healthy.